BioNTech's Cancer Bet Takes Center Stage as Analysts Split on Price Targets
Published on 10/07/2026 at 21:20 | Editorial boerse-global.de
BioNTech's share price barely budged on Wednesday, trading at EUR 85.00 with a modest 0.2% decline, as investors weighed a pair of competing analyst signals against a backdrop of sweeping operational changes at the Mainz-based biotech.
Berenberg analyst Luisa Hector reaffirmed her buy rating on the stock, keeping her price target steady at $140. Her conviction rests largely on upcoming data presentations at the ESMO cancer congress, which opens in Madrid on October 23. The conference ranks among oncology's most closely watched stages for fresh clinical results, and for BioNTech the stakes carry particular strategic weight: after demand for its Covid vaccine business fell sharply, the company has been steering its focus back toward cancer research. According to media reports, Hector is betting that compelling clinical readouts could inject new momentum into the shares.
Morgan Stanley struck a slightly more measured tone on the same day. The US investment bank maintained its Overweight rating but trimmed its target to $114 from $115 — a marginal tweak that signals fine-tuning of its models rather than any shift in conviction. The stock has been trading in a holding pattern as investors await hard data from Madrid, with the current price sitting roughly 20% below its 52-week high.
Insider Sales Follow a Pre-Set Script
Behind the steady share price, CEO Ugur Sahin has been offloading stock in a manner that market watchers describe as routine. SEC filings show Sahin sold tranches of ordinary shares on Monday and Tuesday, with 72,000 shares disposed of on Monday and another 21,000 the following day. The transactions ran through an automated trading plan established under US Rule 10b5-1 — a mechanism that fixes sale timing and volumes well in advance, removing any suspicion of insider-knowledge trading and giving executives an orderly way to divest.
Should investors sell immediately? Or is it worth buying BioNTech?
That plan was set up on June 3. Following the two tranches, the filing lists Sahin as still holding 87,209 ordinary shares directly, keeping him materially invested in the company he co-founded. Because execution is automatic, such pre-arranged sales are not viewed as a warning sign — they reflect no short-term judgment by management on the business outlook.
Three German Plants on the Chopping Block
The insider activity comes alongside a far more consequential restructuring. After failing to find buyers for the affected sites, BioNTech confirmed it will wind down three German production facilities, a move affecting roughly 1,800 employees. The Tübingen plant is slated for closure by the end of 2027, followed by Marburg in early 2028, with manufacturing in Idar-Oberstein ceasing by the end of 2028.
Management attributed the retreat to difficult market and investment conditions as the company pivots away from pandemic-era production capacity. To soften the blow for workers, BioNTech reached an agreement with its works council on socially responsible terms, including supplementary severance payments for staff at all three locations.
BioNTech at a turning point? This analysis reveals what investors need to know now.
For now, the scientific presentations in Madrid loom as the next substantive catalyst that could determine where the stock heads next.
Ad
BioNTech Stock: New Analysis - 7 October
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
